--- title: "China's first invasive BCI human trial: a paralyzed man's thoughts become the controller" date: 2026-11-08 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-stairmed-first-invasive-trial language: en --- # China's first invasive BCI human trial: a paralyzed man's thoughts become the controller > Shanghai's StairMed ran China's first pre-registration invasive brain-computer interface trial, letting a quadriplegic subject control a computer with a thread-thin flexible electrode. A man who had lost both arms and both legs to an electric shock sat in front of a screen. He was not using a keyboard, a mouse, or a joystick. He was playing a racing game by thinking about it. The video, released by a Shanghai company called StairMed (阶梯医疗) in 2023, was the clearest public proof yet that China had moved brain-computer interface (脑机接口) out of the laboratory and into a human body. For a field better known for monkeys and press releases, a paralyzed person moving a cursor with intention alone is a different category of claim. ## What actually happened In early 2023, a surgical team at Huashan Hospital (华山医院), affiliated with Fudan University in Shanghai, implanted StairMed's system into a subject with severe limb loss. The goal was not to cure paralysis but to test whether a person could reliably send commands to a computer using only neural activity recorded from the brain's motor cortex. Within weeks of the procedure, the subject was using the implant to play a racing game and to operate a chess interface — tasks that require continuous, intentional control rather than a single flick of attention. StairMed described the case as China's first pre-registration clinical trial of an invasive brain-computer interface, the stage of testing that comes before a product can be submitted for market approval. The company, founded in 2021, says it was among the earliest groups in the world to run this kind of invasive human study, following pioneers such as Neuralink. That ranking is the company's own framing; what is not in dispute is that the procedure happened and that a person used it. ## How the device works The heart of the system is a flexible electrode thinner than a human hair, paired with a small implant placed in the skull. StairMed's official materials describe the electrode as roughly one micrometer thick, with a cross-section about one three-hundredth the size of a hair, made from materials such as polyimide. Why does thinness matter? Traditional implanted electrodes are rigid metal arrays. The brain, by contrast, is soft and constantly shifts with each heartbeat and head movement. A stiff device irritates tissue and tends to slip or lose signal over time. A flexible electrode (柔性电极) is meant to move with the brain, reducing damage and keeping the connection stable for longer. The implant itself is sealed in biocompatible materials such as titanium alloy and zirconia ceramic, with no battery inside the body. Power and data travel wirelessly through the skull, so the subject is not tethered to a machine by a cable. StairMed says the wireless design lets a user move freely during training rather than staying within a meter of a base station. ## Why this matters for ordinary patients Most people will never receive an invasive implant. But the StairMed trial is a marker for where the technology is heading: not just reading brain signals, but restoring a basic sense of agency to people who have lost the ability to move or speak. Invasive approaches capture far cleaner signals than the caps and headsets worn on the scalp, because they sit close to the source of the electrical activity. That clarity is what makes fine control — steering a cursor, selecting an icon, eventually guiding a robotic arm — possible. StairMed's broader roadmap includes motor control for paralysis, speech restoration for aphasia, and closed-loop (闭环) monitoring and stimulation for conditions such as Parkinson's disease and epilepsy. ## Key takeaways - StairMed ran what it describes as China's first pre-registration invasive BCI trial, implanting a flexible electrode at Huashan Hospital in 2023. - The subject, a person with severe limb loss, used the system to play a game and operate a computer interface within weeks of surgery. - The electrode is roughly one micrometer thick and the implant is battery-free, powered and communicated wirelessly through the skull. - The trial is an early safety and feasibility step, not a finished therapy; market approval has not been granted. - Invasive BCI trades surgical risk for signal quality, aiming at patients conventional rehabilitation cannot help. ## What readers can do now - **Follow the regulatory trail:** Track whether StairMed or peers publish peer-reviewed results or advance to NMPA-registered pivotal trials before treating any single demo as proof. - **Ask the right question about demos:** When a company shows a patient using a BCI, check whether the result is repeated, independently assessed, and tied to a defined clinical endpoint. - **Separate science from spectacle:** A compelling video is a starting point for investigation, not a conclusion about safety or availability. ## Honest limitations This article relies on the company's own announcements and on Chinese media reporting of a 2023 demonstration; we did not find an independent, peer-reviewed publication of the StairMed trial's full results at the time of writing. Specific performance figures circulating in secondary coverage — such as signal-stability percentages from animal tests — could not be verified against a primary source and were therefore omitted. The claim that StairMed was "the world's second" invasive BCI company to reach human trials is the company's characterization and is not independently confirmed here. As with all early-stage neurotechnology, long-term safety, durability of the electrode-tissue interface, and real-world benefit remain open questions until larger, controlled studies report. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-stairmed-first-invasive-trial Free to quote with attribution and a link to the original.